Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
暂无分享,去创建一个
[1] A. Reder. Interferon Therapy of Multiple Sclerosis , 1997 .
[2] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. , 1989, Brain : a journal of neurology.
[3] D. Bourdette,et al. Inter‐ and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS) , 1992, Neurology.
[4] A. S. Hall,et al. NUCLEAR MAGNETIC RESONANCE IMAGING OF THE BRAIN IN MULTIPLE SCLEROSIS , 1981, The Lancet.
[5] G. Rice,et al. Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease? , 1998, Archives of neurology.
[6] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[7] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[8] G. Nahler,et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis , 1997, The Lancet.
[9] H. Weiner,et al. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. , 1983, The New England journal of medicine.
[10] Jeanelle Sheeder,et al. Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .
[11] G. Ebers. Treatment of multiple sclerosis , 1994, The Lancet.
[12] Y. Chernajovsky,et al. Efficient constitutive production of human fibroblast interferon by hamster cells transformed with the IFN-beta 1 gene fused to an SV40 early promoter. , 1984, DNA.
[13] B. Weinshenker,et al. The natural history of multiple sclerosis. , 1995, Neurologic clinics.
[14] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[15] Y. Stern,et al. Cognitive change following MPTP exposure , 1990, Neurology.
[16] S. Dhib-jalbut,et al. Serum interferon β-1a (Avonex) levels following intramuscular injection in relapsing-remitting MS patients , 1998, Neurology.
[17] L. Wilkins. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b , 1996, Neurology.
[18] N. Simonian,et al. “Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.
[19] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[20] L. Jacobs,et al. A brief history of the use of interferons as treatment of multiple sclerosis. , 1994, Archives of neurology.
[21] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[22] J. Noseworthy,et al. A referendum on clinical trial research in multiple sclerosis , 1989, Neurology.
[23] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[24] S. Farmer,et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis , 1997, The Lancet.
[25] O. Andersen,et al. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.
[26] C. Pozzilli,et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. , 1996, Journal of neurology, neurosurgery, and psychiatry.
[27] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[28] F. Barkhof,et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis , 1996, Annals of neurology.
[29] A. Thompson,et al. New treatments for multiple sclerosis: a clinical perspective , 1996, Current opinion in neurology.
[30] B E Kendall,et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. , 1988, Brain : a journal of neurology.
[31] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[32] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.